EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access

T-cell prolymphocytic leukemia, a case report and review of the literature

Luis Manuel GONZáLEZ-RODRíGUEZ, Luis Miguel JUáREZ-Salcedo, Javier Loscertales, Eva Arranz, Jimena Cannata-Ortiz, Javier Ortiz, Maria JOSé LóPEZ DE LA Osa, ADRIáN Alegre, Samir Dalia

Oncology Research · 2025 · 33 (3) · 505-517

DOI: 10.32604/or.2025.058175 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Oncology Research, 2025. Verfasst von Luis Manuel GONZáLEZ-RODRíGUEZ und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, La Princesa University Hospital, Madrid, 28006, Spain. Hauptthemen laut MEDLINE: Leukemia, Prolymphocytic, T-Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T-prolymphocytic leukemia is a rare and aggressive hematological malignancy characterized by the clonal proliferation of mature lymphoid T-cells. The pathogenesis of T-PLL is closely linked to specific chromosomal abnormalities, primarily involving the proto-oncogene T-cell leukemia/lymphoma 1 gene family. Recent advancements in molecular profiling have identified additional genomic aberrations, including those affecting the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway. This case report presents a patient with T-prolymphocytic leukemia whose cytogenetic and molecular analysis revealed a t(X;14)(q28;q11.2) translocation and a STAT5B mutation. Here, we aim to review the genetic and molecular underpinnings of T-prolymphocytic leukemia, as well as current treatment options, with a focus on the anti-CD52 monoclonal antibody alemtuzumab and JAK inhibitors. While alemtuzumab followed by allogeneic hematopoietic stem cell transplantation remains the standard of care for eligible patients, its efficacy is limited and many patients are ineligible. Emerging therapeutic approaches, such as JAK/STAT inhibitors, offer promising potential for improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Prolymphocytic, T-CellHumansMiddle AgedHematopoietic Stem Cell TransplantationMutationProto-Oncogene MasSTAT5 Transcription FactorTranslocation, GeneticFemale

Stichwörter der Autor:innen

AlemtuzumabJAK/STATMTCP1STAT5BT-prolymphocytic leukemia (T-PLL)

Substanzen

MAS1 protein, humanProto-Oncogene MasSTAT5 Transcription FactorSTAT5B protein, human

Autor:innen und Institutionen

  • Hematology Department, La Princesa University Hospital, Madrid, 28006, Spain.
  • Hematology/Oncology, Mercy Clinic Oncology and Hematology-Joplin, Misouri, MO 64804, USA.

Zitieren

APA

GONZáLEZ-RODRíGUEZ, L. M., JUáREZ-Salcedo, L. M., Loscertales, J., Arranz, E., Cannata-Ortiz, J., Ortiz, J., LA Osa, M. J. L., Alegre, A., & Dalia, S. (2025). T-cell prolymphocytic leukemia, a case report and review of the literature. Oncology Research, 33(3), 505-517. https://doi.org/10.32604/or.2025.058175

Vancouver

GONZáLEZ-RODRíGUEZ LM, JUáREZ-Salcedo LM, Loscertales J, Arranz E, Cannata-Ortiz J, Ortiz J, et al. T-cell prolymphocytic leukemia, a case report and review of the literature. Oncology Research. 2025;33(3):505-517. doi:10.32604/or.2025.058175

BibTeX
@article{GONZLEZRODRGUEZ2025,
  author = {GONZáLEZ-RODRíGUEZ, Luis Manuel and JUáREZ-Salcedo, Luis Miguel and Loscertales, Javier and Arranz, Eva and Cannata-Ortiz, Jimena and Ortiz, Javier and LA Osa, Maria JOSé LóPEZ DE and Alegre, ADRIáN and Dalia, Samir},
  title = {T-cell prolymphocytic leukemia, a case report and review of the literature},
  journal = {Oncology Research},
  year = {2025},
  volume = {33},
  number = {3},
  pages = {505--517},
  doi = {10.32604/or.2025.058175}
}
Kostenlos starten →